Wednesday November 29, 10:23 am Eastern Time
Press Release
SOURCE: BioStratum Incorporated
BioStratum Signs Agreement With Shire for
Pyridorin(TM)XR
RESEARCH TRIANGLE PARK, N.C., Nov. 29 /PRNewswire/ --
BioStratum Incorporated has signed a Development and License Agreement with Shire Laboratories Incorporated
to develop an extended release (XR) version of BioStratum's lead drug candidate, Pyridorin(TM). Currently in
Phase II clinical trials, Pyridorin(TM) treats diabetic kidney disease.
``Formulating Pyridorin(TM) into a single daily dosage will be more convenient for a patient and has the added
clinical benefit of assuring a stable plasma concentration of Pyridorin(TM),'' said Dr. Claus Kuhl, president and
chief executive officer of BioStratum. He added, ``This agreement is intended to ensure that we have an extended
release version of Pyridorin(TM) in time for our Phase III clinical trials.''
The application of our expertise in drug delivery to this exciting new drug is an innovative way to modify the
pharmacokinetic characteristics of Pyridorin(TM),`` said Jack Khattar, president and chief executive officer of
Shire Laboratories. ''Our leadership in oral controlled release drug delivery provides BioStratum with access to
multiple technologies which will be exploited to address the product's objectives,`` he added.
Pyridorin(TM) is BioStratum's lead drug and a result of BioStratum's leadership position in research and
development related to the body's basal lamina. In animal models of diabetic nephropathy, Pyridorin(TM) has
been shown to inhibit the formation of advanced glycation end products (A.G.E.s) which are believed to damage
the kidney function and ultimately lead to kidney failure. |
